RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES 11 optogenetics, AAV vectors, transferring genetic material into cells, In-licensed Patent Rights processes to manufacture and purify our product candidates, As of February 28, 2018, we in-licensed at least 16 U.S. and optics and other proprietary technologies and processes related foreign patent applications and at least 8 U.S. and foreign patents, to our product candidates. We also possess significant know-how that have been filed by or on behalf of our licensors. and trade secrets relating to our product candidates. Product candidate Owner Title Patent Term Countries Current status LHON (GS010) Inserm Expression of 2026 United States European Union: granted, mitochondrial European Union no opposition filed protein by an United States: one patent enhanced allotopic granted and one divisional approach pending (US’740: accelerated examination ongoing) RP (GS030) University Adeno-associated 2032 Australia, Canada Granted in US, EP, JP, CN of California virus virions with Singapore, Israel, and AU (Adverum) variant capsid and China, European methods of use Union, Korea, Japan, thereof United States (2x), Russia, Mexico RP (GS030) M.I.T. Channelrhodopsins 2032 Korea, United States, United States: pending for optical control European Union, Granted in Europe of cells Hong Kong With regard to the GS010 product candidate, as discussed above, a granted European patent directed to ChrimsonR. The granted we have in-licensed a patent family from Inserm Transfert that European patent and pending applications, if issued, are expected relates to an expression vector for the delivery of a protein into to expire in 2032, subject to possible patent term extensions. In the mitochondrion of a mammalian cel l and the uses thereof. addition, as discussed above, we have non- exclusively in-licensed This patent family contains one pending U.S. application and one from Adverum a patent family that relates to the AAV2 7 m8 granted European patent. The granted European patent and the vector, with patents granted in the U.S., Europe, China, Australia, pending U.S. application, if issued, are expected to expire in 2026, and Japan, and patent applications pending in Canada, Israel, subject to possible patent term extensions. South Korea, Mexico, Singapore, Russia, South Africa and Brazil, With regard to the GS030 product candidate, as discussed above, where the granted patents and pending applications, if issued, we have exclusively in-licensed from M.I.T. patent applications are expected to expire in 2032, subject to possible patent term pending in the United States, Hong Kong and South Korea and extensions. Product candidate Owner Title Patent Filing date Current status Application Number RP (GS030) GenSight Biologics Optogenetic visual US62/329692 29/04/2016 International UPMC restoration using phase CNRS ChrimsonR INSERM RP (GS030) GenSight Biologics Device for illuminating EP16305741.7 17/06/2016 International UPMC an object with a phase CNRS controlled light intensity INSERM and associated method RP (GS030) GenSight Biologics Medical device EP16306005.6 02/08/2016 International UPMC intended to be worn in phase CNRS front of the eyes INSERM 138– GENSIGHT BIOLOGICS – 2017 Registration Document